Bio-Rad Laboratories Inc (NYSE: BIO) shares are trading lower after the company lowered its annual revenue growth forecast, citing the uncertain pace of the biopharma sector's recovery and the
Novo Nordisk A/S (NYSE: NVO) investors and analysts eagerly await the company's third-quarter results, hoping for clarity on when supply limitations for its weight-loss drug, Wegovy, in the U.S.
Sanofi SA (NASDAQ: SNY) plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment in its drug-development pipeline and cut costs.
Biogen Inc. (NASDAQ: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau,